Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 6;9(1):eade9120.
doi: 10.1126/sciadv.ade9120. Epub 2023 Jan 6.

Arginine limitation drives a directed codon-dependent DNA sequence evolution response in colorectal cancer cells

Affiliations

Arginine limitation drives a directed codon-dependent DNA sequence evolution response in colorectal cancer cells

Dennis J Hsu et al. Sci Adv. .

Abstract

Utilization of specific codons varies between organisms. Cancer represents a model for understanding DNA sequence evolution and could reveal causal factors underlying codon evolution. We found that across human cancer, arginine codons are frequently mutated to other codons. Moreover, arginine limitation-a feature of tumor microenvironments-is sufficient to induce arginine codon-switching mutations in human colon cancer cells. Such DNA codon switching events encode mutant proteins with arginine residue substitutions. Mechanistically, arginine limitation caused rapid reduction of arginine transfer RNAs and the stalling of ribosomes over arginine codons. Such selective pressure against arginine codon translation induced an adaptive proteomic shift toward low-arginine codon-containing genes, including specific amino acid transporters, and caused mutational evolution away from arginine codons-reducing translational bottlenecks that occurred during arginine starvation. Thus, environmental availability of a specific amino acid can influence DNA sequence evolution away from its cognate codons and generate altered proteins.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.. Arginine codons and residues are frequently lost and are associated with an increase in ASS1 expression.
(A) Heatmap depicting codons gained (red) and lost (blue) across the TCGA. Gains and losses are normalized to the total number of missense and silent mutation events per sample for each cancer type. (B) Qualitative chord diagram showing amino acid switching events in cancer after adjustment from simulations. Ribbons that directly touch a column segment indicate loss of that specific amino acid codon during a mutational event and gain of the corresponding amino acid codon in which the ribbon terminates. Ribbons that begin and end at the same amino acid represent synonymous mutations. (C) Arginine codon–switching events observed versus predicted. Clusters were assigned with Affinity Propagation. (D) ASS1 expression in colorectal cancer (CRC) samples with either a high-degree or low-degree of arginine codon–switching events (n = 96 per group) with whiskers denoting minimum and maximum values. (DESeq2, ****Padjusted < 0.0001).
Fig. 2.
Fig. 2.. Arginine codon losses are associated with increased dependence on extracellular arginine and nucleotide pool instability during starvation.
(A) Cell line viability (means ± SD) under low-arginine (12.5 μM) conditions. (n = 3 per group). (B) Effect of nucleotide supplementation on colon cancer cell viability with arginine deprivation (n = 6 per group, two-tailed t test). (C) Metabolite profiling differences after exposure to low-arginine concentrations for 24 hours. Each point represents a purine/pyrimidine pathway metabolite and is the average log2 fold change (log2FC) difference between high-arginine codon–mutated lines and low-arginine codon mutated lines (one-sample t test with μ0 = 0). (D) Volcano plot of metabolite changes following arginine deprivation. Only detected citric acid cycle, urea cycle, amino acids, and nucleotide intermediates are labeled. (*P < 0.05, **P < 0.01, and ***P < 0.001). NT, nucleotides; TTP, thymidine 5'-triphosphate; UTP, uridine 5′-triphosphate; GMP, guanosine 5′-monophosphate; GDP, guanosine diphosphate.
Fig. 3.
Fig. 3.. Arginine deprivation reduces arginine tRNA availability, increases arginine ribosome localization, and reduces arginine usage in the tumor proteome.
(A) tRNA quantification as assessed via Northern blot. Each dot represents the average abundance in an independent colon cancer or gastric cancer cell line (n = 7 per group, one-sample t test with μ0 = 0). (B) Ribosome A-site localization counts from ribosomal profiling experiments under starved or fed conditions. Circle size is scaled to counts. (C) Amino acid (AA) usage in genes that are highly expressed under fed or starved states. (D) Arginine codon abundance in genes expressed in fed or starved states (n > 450 per group, two-tailed Mann-Whitney test). Proteins are stratified on the basis of the top 10% most changed in either fed or starved states. (*P < 0.05, ***P < 0.001, and ****P < 0.0001). ns, not significant.
Fig. 4.
Fig. 4.. Arginine deprivation promotes arginine-losing mutations.
(A) Schematic of arginine deprivation experiments. (B) Arginine codon changes in cells serially passaged in either full media or low-arginine media (n = 3 per group, two-tailed paired t test). (C) Arginine codon changes in proteins that are increased during the fed or arginine-starved states (n = 3 per group, two-tailed t test). (D) Histidine codon changes in proteins that are increased during the fed or arginine-starved states (n = 3 per group, two-tailed t test). (E) Arginine codon changes in patient-derived xenograft (PDX) tumors that underwent multiple rounds of in vivo liver metastatic selection (n = 3 per group, one-tailed paired t test). (*P < 0.05 and **P < 0.01).
Fig. 5.
Fig. 5.. Arginine deprivation drives a codon-dependent DNA sequence evolution response.
A model depicting how arginine deprivation results in multiple consequences including nucleotide pool imbalances and impaired translation of specific arginine codons, ultimately resulting in the loss of arginine codons in CRC genomes.

Update of

References

    1. R. Hershberg, D. A. Petrov, Selection on codon bias. Annu. Rev. Genet. 42, 287–299 (2008). - PubMed
    1. The Cancer Genome Atlas Research Network, J. N. Weinstein, E. A. Collisson, G. B. Mills, K. R. M. Shaw, B. A. Ozenberger, K. Ellrott, I. Shmulevich, C. Sander, J. M. Stuart, The Cancer Genome Atlas pan-cancer analysis project. Nat. Genet. 45, 1113–1120 (2013). - PMC - PubMed
    1. L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge, S. A. J. R. Aparicio, S. Behjati, A. V. Biankin, G. R. Bignell, N. Bolli, A. Borg, A.-L. Børresen-Dale, S. Boyault, B. Burkhardt, A. P. Butler, C. Caldas, H. R. Davies, C. Desmedt, R. Eils, J. E. Eyfjörd, J. A. Foekens, M. Greaves, F. Hosoda, B. Hutter, T. Ilicic, S. Imbeaud, M. Imielinski, N. Jäger, D. T. W. Jones, D. Jones, S. Knappskog, M. Kool, S. R. Lakhani, C. López-Otín, S. Martin, N. C. Munshi, H. Nakamura, P. A. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J. V. Pearson, X. S. Puente, K. Raine, M. Ramakrishna, A. L. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T. N. Schumacher, P. N. Span, J. W. Teague, Y. Totoki, A. N. J. Tutt, R. Valdés-Mas, M. M. van Buuren, L. van ‘t Veer, A. Vincent-Salomon, N. Waddell, L. R. Yates; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, J. Zucman-Rossi, P. A. Futreal, U. M. Dermott, P. Lichter, M. Meyerson, S. M. Grimmond, R. Siebert, E. Campo, T. Shibata, S. M. Pfister, P. J. Campbell, M. R. Stratton, Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013). - PMC - PubMed
    1. L. B. Alexandrov, M. R. Stratton, Mutational signatures: The patterns of somatic mutations hidden in cancer genomes. Curr. Opin. Genet. Dev. 24, 52–60 (2014). - PMC - PubMed
    1. M. Pan, M. A. Reid, X. H. Lowman, R. P. Kulkarni, T. Q. Tran, X. Liu, Y. Yang, J. E. Hernandez-Davies, K. K. Rosales, H. Li, W. Hugo, C. Song, X. Xu, D. E. Schones, D. K. Ann, V. Gradinaru, R. S. Lo, J. W. Locasale, M. Kong, Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat. Cell Biol. 18, 1090–1101 (2016). - PMC - PubMed